Discount pricing and poor first day defies the recent trend for floating device makers.
It takes more than a pandemic to stop medical device companies merging.
2019 was an average year for medtech M&A. 2020, not so much.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.